Xinjiang Tianshun Supply Chain (SHE:002800) will deregister an internet services subsidiary after getting board approval, according to a Wednesday filing on the Shenzhen bourse.
Horgos Dadao Technology will be deregistered after losses in the first quarter.
The logistics company's shares fell 2% at the close.
Nissei Plastic Industrial and Toyo Innovex, both wholly owned subsidiaries of GMS Group (TYO:544A), have resolved at their extraordinary general meetings to distribute all GMS Group shares they hold back to the parent company as a dividend in kind.The injection moulding machine maker said the move is required under the Companies Act, which mandates that subsidiaries dispose of parent company shares within an appropriate period.As a result, GMS Group will acquire 1.54 million treasury shares on May 28. Following the acquisition, total issued shares excluding treasury shares will decrease to 69.4 million shares, a reduction of 1.54 million shares.
LY Corp. (TYO:4689) received notification from Thai authorities on May 14, confirming that no approvals or permits are required for the additional acquisition of shares in Line Man Corp. through its subsidiary.The company had already integrated Line Man as a consolidated subsidiary on September 30, 2025, while awaiting the final conclusion of the cross-border regulatory review. With the statutory clearance now finalized, the Tokyo-based tech firm plans to formally execute and settle the additional share acquisition by August 2026.LY Corp. projects holding over 81 million Line Man Corp. shares, giving them 60.9% of the voting rights, once the transaction is finished.
Kissei Pharmaceutical (TYO:4547) has submitted a new drug application in Japan seeking manufacturing and marketing approval for olutasidenib, a treatment for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.The drug works by inhibiting the IDH1 metabolic enzyme to restore normal cell differentiation and was originally discovered by Forma Therapeutics, according to at Tokyo bourse filing on Wednesday.Kissei acquired exclusive development and sales rights for Japan, South Korea, and Taiwan from Rigel Pharmaceuticals in September 2024, following olutasidenib's U.S. approval in December 2022.Kissei remains focused on developing new treatments for rare diseases with limited therapeutic options.The submission's impact is already reflected in the company's consolidated financial forecast for the fiscal year ending March 31, 2027.